API Family
Obeticholic Acid
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
7-epi-Obeticholic Acid 3-Obeticholate Ester, 1908444-28-9
Application Notes
Useful research chemical for a range of applications
Hazard Compound
No -Refer MSDS for accurate information
7-epi-Obeticholic Acid 3-Obeticholate Ester is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
7-epi-Obeticholic Acid 3-Obeticholate Ester usage and description
7-epi-Obeticholic Acid (7-ECA) is a synthetic bile acid derivative that has been shown to have potential therapeutic effects in the treatment of various liver diseases. It is a potent agonist of the farnesoid X receptor (FXR), a nuclear receptor that plays a critical role in regulating bile acid homeostasis, lipid metabolism, and inflammation. By activating FXR, 7-ECA can reduce the accumulation of toxic bile acids in the liver, improve insulin sensitivity, and reduce hepatic inflammation and fibrosis.
One of the most promising derivatives of 7-ECA is the 3-Obeticholate Ester (3-OBE), which is a prodrug that is rapidly converted to 7-ECA in vivo. This esterification strategy enhances the bioavailability and pharmacokinetic properties of 7-ECA, allowing for more efficient delivery and targeted activation of FXR.
Chemically, 7-ECA and 3-OBE belong to a class of compounds known as bile acids, which are natural detergents that play an essential role in the digestion and absorption of dietary fats and fat-soluble vitamins. Bile acids are synthesized in the liver from cholesterol and are secreted into the small intestine, where they emulsify fats and facilitate their absorption. Bile acids are also involved in the regulation of glucose and lipid metabolism, and their dysregulation has been implicated in the pathogenesis of various metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and atherosclerosis.
In conclusion, 7-ECA and its derivatives represent a promising class of compounds for the treatment of liver and metabolic diseases, and ongoing research is focused on elucidating their mechanisms of action and optimizing their therapeutic potential.
